SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are trending as investors rally ahead of the upcoming earnings report, fueled by optimism over the company's AI-driven cloud infrastructure demand and a raised price target from Morgan Stanley. While the community is largely bullish, some traders debate the potential impact of high capital expenditures and heavy debt on future performance.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending as investors anticipate upcoming developments at the company's investor day, with discussion focused on the potential for updated technology roadmaps and revenue outlooks following recent acquisitions. The conversation remains polarized, featuring a mix of optimism regarding quantum computing milestones and bearish debate over valuation and short-term volatility.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is receiving attention as traders anticipate its upcoming earnings report following a recent $100 million U.S. government funding award, with debate focused on whether the company's technical milestones and institutional backing justify its current valuation. Community sentiment remains mixed, as some investors express skepticism regarding the company's path to profitability while others view the stock as a long-term play on the quantum sector.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trading lower following news that a competitor's Phase 3 trial in the DM1 space failed to meet primary endpoints, sparking fears that this might signal a broader challenge for similar gene therapy treatments. While some traders view this as a negative read-through that questions the efficacy of the DMPK knockdown mechanism, others argue the sell-off is an overreaction or sympathy move, suggesting the company's established Duchenne muscular dystrophy franchise remains robust.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as traders react to its first-ever IPO underwriting role for Oura and significant growth in its prediction markets and Robinhood Chain fee revenue. The stock's recent rally has sparked intense debate, with bullish investors pointing to the company's expanding financial ecosystem while some retail traders continue to express skepticism and frustration rooted in past platform controversies.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following the finalization of a $100 million funding agreement with the U.S. Department of Commerce under the CHIPS and Science Act. While some traders view this government backing as a significant validation and catalyst for long-term growth, others remain skeptical, citing ongoing concerns about the company's path to commercial profitability and recent leadership changes.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as the community highlights the FDA's acceptance of the Biologics License Application (BLA) for its hereditary angioedema (HAE) treatment, lonvoguran ziclumeran (lonvo-z), with Priority Review. Traders are expressing strong bullish sentiment regarding the company's progress toward commercialization, bolstered by a solid cash runway and significant institutional accumulation, while some continue to debate potential short squeeze dynamics given the stock's high short interest.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals shares are seeing increased volatility and community attention amid ongoing speculation regarding potential buyout interest and the company's recent strategic pivot to acquire external rare-disease assets. Traders remain divided, with some expressing frustration over the stock's long-term performance and price action, while others highlight the potential value of its HAE franchise.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG - ADR

Novartis AG

Novartis is trending as investors react to the company's recent strategic $1.4 billion acquisition of Tourmaline Bio, which adds the Phase III cardiovascular drug pacibekitug to its pipeline, as well as the successful Phase III study results for its Sjögren's disease drug, ianalumab.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is facing intense selling pressure as traders speculate on potential margin compression due to rising beef costs and broader consumer spending concerns. While bearish sentiment is driving the stock toward new 52-week lows, some investors view the current price as a value opportunity for a defensive blue-chip stock with a strong long-term dividend history.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PACB 
The goal of the NIH-led Bio Genesis Mission is to double the pace of biomedical innovation, from discovery to health impact, within the next five to 10 years. 

The Bio Genesis Mission, NIH&#39;s contribution to that national effort, represents a major initiative to accelerate biomedical discovery and improve health outcomes by leveraging artificial intelligence, advanced computing, innovative approaches to policy and governance, and public-private partnerships.

This is more than applying AI to existing research workflows. It is about reimagining how researchers, institutions, data resources, and scientific infrastructure work together to solve the biomedical challenges that matter most to American patients and families, while safeguarding the sensitive data that makes this research possible.

This is an opportunity for PacBio. They’ve already shown succes with Google when utilizing AI on the WGS data.

Maxim Sorokin

Astro

Dr.D.

Arek

Scott

StockTwits for iOS

Pacific Biosciences of California Inc

 
The goal of the NIH-led Bio Genesis Mission is to double the pace of biomedical innovation, from discovery to health impact, within the next five to 10 years. 

The Bio Genesis Mission, NIH's contribution to that national effort, represents a major initiative to accelerate biomedical discovery and improve health outcomes by leveraging artificial intelligence, advanced computing, innovative approaches to policy and governance, and public-private partnerships.

This is more than applying AI to existing research workflows. It is about reimagining how researchers, institutions, data resources, and scientific infrastructure work together to solve the biomedical challenges that matter most to American patients and families, while safeguarding the sensitive data that makes this research possible.

This is an opportunity for PacBio. They’ve already shown succes with Google when utilizing AI on the WGS data.